Gentherm Reports Record Third Quarter, Nine-Month Revenues
| PR Newswire Association LLC |
"We broke
Third Quarter Financial Highlights
Revenues for the 2013 third quarter increased 21 percent to
Higher CCS revenues were due to new program launches, including the Cadillac CTX and the North American variant of the Hyundai Sonata, and additional volume on programs launched during last year's third quarter, including the redesigned
W.E.T. revenue increases resulted from strong automotive volumes in
Foreign currency translation of the Company's Euro denominated revenue for this year's third quarter, which was approximately €35.7 million compared with €31.9 million during the prior year period, benefited revenue results by approximately
Net income attributable to common shareholders for the 2013 third quarter was
Adjusting for the impact of the W.E.T. acquisition transaction expenses,
Further non-cash purchase accounting impacts associated with the W.E.T. acquisition are detailed in the Acquisition Transaction Expenses, W.E.T. Purchase Accounting Impacts and Other Effects table accompanying the release.
Gross margin as a percentage of revenue for this year's third quarter was 26.8 percent compared with 26.1 percent for the third quarter of 2012. This increase was due to a favorable change in product mix and greater coverage of fixed manufacturing costs at the higher volume levels.
Adjusted EBITDA for the 2013 third quarter was
The Company's balance sheet as of
Year-to-Date Summary
For the first nine months of 2013, revenues increased 18 percent to
Foreign currency translation of the Company's Euro denominated revenue for the first nine months of 2013, which was approximately €106.1 million compared with €95.5 million during the prior year period, increased the US Dollar reported revenue by approximately
Net income attributable to common shareholders for the first nine months of 2013 was
Adjusting for the impact of the W.E.T. acquisition transaction expenses and the
Further non-cash purchase accounting impacts associated with the W.E.T. acquisition are detailed in the Acquisition Transaction Expenses, W.E.T. Purchase Accounting Impacts and Other Effects table accompanying the release.
Gross margin as a percentage of revenue for first nine months of 2013 was 26.1 percent compared with 25.5 percent for the first nine months of 2012.
Adjusted EBITDA for the first nine months of 2013 was
Revaluation of Derivatives
For the third quarter and first nine months of this year, the Company recorded foreign currency losses of
Research and Development, Selling, General and Administrative (SG&A) Expenses
Net research and development expenses for this year's third quarter and first nine months were up
SG&A expenses for the third quarter and first nine months of 2013, which included the above mentioned
Guidance
Barring unforeseen economic turbulence, including worsening of the European market or unfavorable fluctuations of the Euro exchange rate, the 2013 revenue growth outlook remains strong. The Company expects that fourth quarter revenue will be slightly lower sequentially from the third quarter, but still represent a significant increase from the prior year fourth quarter. That would set the full year growth rate at 17 percent over 2012 revenues of
Conference Call
As previously announced,
About
Except for historical information contained herein, statements in this release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements regarding future sales, products, opportunities, markets, expenses and profits. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. Those risks include, but are not limited to, risks that sales may not significantly increase, additional financing requirements may not be available, new competitors may arise and adverse conditions in the industry in which the Company operates may negatively affect its results. Those and other risks are described in the Company's annual report on Form 10-K for the year ended
|
Contact: |
Allen & Caron Inc |
|
|
|
| <br /> |
|
|
(949) 474-4300 |
TABLES FOLLOW
|
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited) |
||||||||||||||
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||
|
2013 |
2012 |
2013 |
2012 |
|||||||||||
|
Product revenues |
$ |
171,182 |
$ |
141,058 |
$ |
479,792 |
$ |
406,737 |
||||||
|
Cost of sales |
125,265 |
104,203 |
354,672 |
303,110 |
||||||||||
|
Gross margin |
45,917 |
36,855 |
125,120 |
103,627 |
||||||||||
|
Operating expenses: |
||||||||||||||
|
Net research and development expenses |
12,718 |
10,257 |
36,962 |
30,566 |
||||||||||
|
Acquisition transaction expenses |
326 |
— |
1,911 |
— |
||||||||||
|
Selling, general and administrative |
18,319 |
16,560 |
53,483 |
45,972 |
||||||||||
|
Total operating expenses |
31,363 |
26,817 |
92,356 |
76,538 |
||||||||||
|
Operating income |
14,554 |
10,038 |
32,764 |
27,089 |
||||||||||
|
Interest expense |
(1,062) |
(898) |
(2,916) |
(3,082) |
||||||||||
|
Revaluation of derivatives |
217 |
(993) |
1,201 |
(1,056) |
||||||||||
|
Foreign currency gain (loss) |
(1,612) |
(421) |
(1,514) |
2,357 |
||||||||||
|
Income (loss) from equity investment |
77 |
3 |
319 |
(228) |
||||||||||
|
Other income |
310 |
691 |
859 |
|||||||||||
|
Earnings before income tax |
12,365 |
8,039 |
30,545 |
25,939 |
||||||||||
|
Income tax expense |
3,600 |
2,366 |
6,343 |
7,324 |
||||||||||
|
Net income |
8,765 |
5,673 |
24,202 |
18,615 |
||||||||||
|
Gain attributable to non-controlling interest |
(63) |
(1,672) |
(1,340) |
(4,491) |
||||||||||
|
Net income attributable to |
8,702 |
4,001 |
22,862 |
14,124 |
||||||||||
|
Convertible preferred stock dividends |
(159) |
(1,516) |
(1,622) |
(5,521) |
||||||||||
|
Net income attributable to common shareholders |
$ |
8,543 |
$ |
2,485 |
$ |
21,240 |
$ |
8,603 |
||||||
|
Basic earnings per share |
$ |
0.25 |
$ |
0.08 |
$ |
0.64 |
$ |
0.31 |
||||||
|
Diluted earnings per share |
$ |
0.24 |
$ |
0.08 |
$ |
0.63 |
$ |
0.30 |
||||||
|
Weighted average number of shares – basic |
34,447 |
29,619 |
33,261 |
28,177 |
||||||||||
|
Weighted average number of shares – diluted |
34,886 |
30,003 |
33,584 |
28,676 |
||||||||||
|
RECONCILIATION OF ADJUSTED EBITDA TO NET INCOME (Unaudited, in thousands) |
||||
|
Three Months Ended September 30, |
Nine Months Ended September 30, </p> |
|||
|
2013 |
2012 |
2013 |
2012 |
|
|
Net income |
$ 8,765 |
$ 5,673 |
$ 24,202 |
$ 18,615 |
|
Add Back: |
||||
|
Income tax expense |
3,600 |
2,366 |
6,343 |
7,324 |
|
Interest expense |
1,062 |
898 |
2,916 |
3,082 |
|
Depreciation and amortization |
7,572 |
7,280 |
22,830 |
22,265 |
|
Adjustments: |
||||
|
Acquisition transaction expense |
326 |
– |
1,911 |
– |
|
Unrealized currency loss |
1,206 |
2,505 |
1,129 |
1,913 |
|
Unrealized revaluation of derivatives |
(1,274) |
<p class="prnews_p">(252) |
(3,414) |
(1,482) |
|
Adjusted EBITDA |
$ 21,257 |
$ 18,470 |
$ 55,917 |
$ 51,717 |
Use of Non-GAAP Financial Measures
In evaluating its business,
The term Adjusted EBITDA is not defined under GAAP, and is not a measure of operating income, operating performance or liquidity presented in accordance with GAAP. Adjusted EBITDA has limitations as an analytical tool, and when assessing the Company's operating performance, investors should not consider Adjusted EBITDA in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with GAAP.
|
|
||||||||
|
ACQUISITION TRANSACTION EXPENSES, W.E.T. PURCHASE ACCOUNTING IMPACTS AND OTHER EFFECTS |
||||||||
|
(In thousands, except per share data) |
||||||||
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
Future Full Year Periods (estimated) |
||||||
|
2013 |
2012 |
2013 |
2012 |
2013 |
2014 |
2015 |
Thereafter |
|
|
Transaction related current expenses |
||||||||
|
Acquisition transaction expenses |
$ 326 |
$ – |
$ 1,911 |
$ – |
$ 1,911 |
$ – |
$ – |
$ – |
|
Non-cash purchase accounting impacts |
||||||||
|
Customer relationships amortization |
$ 1,987 |
$ 1,924 |
$ 5,927 |
$ 5,771 |
$ 8,105 |
$ 8,105 |
$ 8,105 |
$ 41,805 |
|
Technology amortization |
833 |
807 |
2,486 |
2,420 |
3,399 |
3,399 |
3,399 |
6,397 |
|
Product development costs amortization |
550 |
520 |
1,641 |
1,561 |
2,244 |
2,244 |
1,271 |
51 |
|
$ 3,370 |
$ 3,251 |
$ 10,054 |
$ 9,752 |
$ 13,748 |
$ 13,748 |
$ 12,775 |
$ 48,253 |
|
|
Tax effect |
(907) |
(753) |
(3,071) |
(2,259) |
(3,926) |
(3,184) |
(2,959) |
(11,175) |
|
Net income effect |
2,789 |
2,498 |
8,894 |
7,493 |
11,733 |
10,564 |
9,816 |
37,078 |
|
Non-controlling interest effect |
(26) |
(602) |
(155) |
(1,805) |
(397) |
(63) |
(59) |
(222) |
|
Net income available to shareholders effect |
$ 2,763 |
$ 1,896 |
$ 8,739 |
$ 5,688 |
$ 11,336 |
$ 10,501 |
$ 9,757 |
$ 36,856 |
|
Earnings (loss) per share - difference |
||||||||
|
Basic |
$ 0.08 |
$ 0.06 |
$ 0.26 |
$ 0.20 |
||||
|
Diluted |
$ 0.08 |
$ 0.06 |
$ 0.26 |
$ 0.20 |
||||
|
Series C Preferred Stock dividend |
$ 159 |
$ 1,516 |
$ 1,622 |
$ 5,521 |
$ 1,622 |
$ – |
$ – |
$ – |
|
Earnings (loss) per share - difference |
||||||||
|
Basic |
$ 0.00 |
$ 0.05 |
$ 0.05 |
$ 0.20 |
||||
|
Diluted |
$ 0.00 |
$ 0.05 |
$ 0.05 |
$ 0.19 |
||||
|
CONSOLIDATED CONDENSED BALANCE SHEETS (In thousands, except share data) |
||||||
|
2013 |
December 31, 2012 |
|||||
|
(unaudited) |
||||||
|
ASSETS |
||||||
|
Current Assets: |
||||||
|
Cash & cash equivalents |
$ |
36,003 |
$ |
58,152 |
||
|
Accounts receivable, less allowance of |
122,330 |
102,261 |
||||
|
Inventory: |
||||||
|
Raw Materials |
35,388 |
28,279 |
||||
|
Work in process |
2,720 |
2,461 |
||||
|
Finished goods |
24,698 |
23,016 |
||||
|
Inventory, net |
62,806 |
53,756 |
||||
|
Derivative financial instruments |
292 |
160 |
||||
|
Deferred income tax assets |
14,389 |
15,006 |
||||
|
Prepaid expenses and other assets |
15,222 |
12,809 |
||||
|
Total current assets |
251,042 |
242,144 |
||||
|
Property and equipment, net |
73,608 |
55,010 |
||||
|
Goodwill |
25,300 |
24,729 |
||||
|
Other intangible assets |
85,827 |
95,870 |
||||
|
Deferred financing costs |
1,246 |
1,880 |
||||
|
Deferred income tax assets |
7,772 |
5,361 |
||||
|
Derivative financial instruments |
2,403 |
4,141 |
||||
|
Other non-current assets |
10,701 |
10,062 |
||||
|
Total assets |
$ |
457,899 |
$ |
439,197 |
||
|
LIABILITIES AND SHAREHOLDERS' EQUITY |
||||||
|
Current Liabilities: |
||||||
|
Accounts payable |
$ |
55,176 |
$ |
42,508 |
||
|
Accrued liabilities |
57,696 |
54,157 |
||||
|
Current maturities of long-term debt |
22,164 |
17,218 |
||||
|
Derivative financial instruments |
2,652 |
3,326 |
||||
|
Total current liabilities |
137,688 |
117,209 |
||||
|
Pension benefit obligation |
4,961 |
5,009 |
||||
|
Other liabilities |
2,836 |
4,540 |
||||
|
Long-term debt, less current maturities |
65,270 |
39,734 |
||||
|
Derivative financial instruments |
9,553 |
13,245 |
||||
|
Deferred income tax liabilities |
21,945 |
21,828 |
||||
|
Total liabilities |
242,253 |
201,565 |
||||
|
Series C Convertible Preferred Stock |
— |
22,469 |
||||
|
Shareholders' equity: |
||||||
|
Common Stock: |
||||||
|
No par value; 55,000,000 shares authorized, 34,689,569 and 29,818,225 issued and outstanding at |
229,021 |
166,309 |
||||
|
Paid-in capital |
(10,013) |
24,120 |
||||
|
Accumulated other comprehensive income (expense) |
3,855 |
(11,231) |
||||
|
Accumulated deficit |
(8,408) |
(17,383) |
||||
|
Total |
214,455 |
161,815 |
||||
|
Non-controlling interest |
1,191 |
53,348 |
||||
|
Total shareholders' equity |
215,646 |
215,163 |
||||
|
Total liabilities and shareholders' equity |
$ |
457,899 |
$ |
439,197 |
||
|
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) |
||||||
| </td> | ||||||
|
Nine Months Ended September 30, |
||||||
|
2013 |
2012 |
|||||
|
Operating Activities: |
||||||
|
Net income |
$ |
24,202 |
$ |
18,615 |
||
|
Adjustments to reconcile net income to cash provided by operating activities: |
||||||
|
Depreciation and amortization |
23,467 |
22,737 |
||||
|
Deferred tax provision |
(1,138) |
2,134 |
||||
|
Stock compensation |
1,861 |
911 |
||||
|
Defined benefit plan expense |
(159) |
(303) |
||||
|
Provision of doubtful accounts |
369 |
(305) |
||||
|
Gain on revaluation of financial derivatives |
(2,859) |
(1,064) |
||||
|
Loss (gain) on equity investment |
(318) |
228 |
||||
|
Loss on sale of property, plant and equipment |
48 |
53 |
||||
|
Excess tax benefit from equity awards |
(1,317) |
(1,577) |
||||
|
Changes in operating assets and liabilities: |
||||||
|
Accounts receivable |
(19,606) |
(16,728) |
||||
|
Inventory |
(8,824) |
(4,250) |
||||
|
Prepaid expenses and other assets |
(2,458) |
(7,264) |
||||
|
Accounts payable |
11,250 |
4,622 |
||||
|
Accrued liabilities |
4,099 |
10,715 |
||||
|
Net cash provided by operating activities |
28,617 |
28,524 | ||||
|
Investing Activities: |
||||||
|
Purchase of non-controlling interest |
(46,835) |
— |
||||
|
Purchase of derivative financial instruments |
— |
(7,787) |
||||
|
Proceeds from the sale of property, plant and equipment |
7 |
20 |
||||
|
Purchase of property and equipment |
(30,016) |
(15,344) |
||||
|
Loan to equity investment |
— |
(590) |
||||
|
Cash invested in corporate owned life insurance |
(266) |
(265) |
||||
|
Patent costs |
— |
(1,744) |
||||
|
Net cash used in investing activities |
(77,110) |
(25,710) |
||||
|
Financing Activities: |
||||||
|
Borrowing of debt |
48,923 |
3,286 |
||||
|
Repayments of debt |
(18,966) |
(19,149) |
||||
|
Distributions paid to non-controlling interests |
(3) |
(290) |
||||
|
Proceeds from public offering of common stock |
— |
75,487 |
||||
|
Excess tax benefit from equity awards |
1,317 |
1,577 |
||||
|
Cash paid to Series C Preferred Stock Holders |
(9,142) |
(17,340) |
||||
|
Proceeds from sale of W.E.T. equity to non-controlling interest |
— |
1,921 |
||||
|
Proceeds from the exercise of Common Stock options |
2,901 |
733 |
||||
|
Net cash provided by financing activities |
25,030 |
46,225 |
||||
|
Foreign currency effect |
1,314 |
(599) |
||||
|
Net increase (decrease) in cash and cash equivalents |
(22,149) |
48,440 |
||||
|
Cash and cash equivalents at beginning of period |
58,152 |
23,839 |
||||
|
Cash and cash equivalents at end of period |
$ |
36,003 |
$ |
72,279 |
||
|
Supplemental disclosure of cash flow information: |
||||||
|
Cash paid for taxes |
$ |
7,174 |
$ |
5,678 |
||
|
Cash paid for interest |
$ |
2,249 |
$ |
2,787 |
||
|
Supplemental disclosure of non-cash transactions: |
||||||
|
Common stock issued to Board of Directors and employees |
$ |
1,028 |
$ |
314 |
||
|
Issuance of common stock to non-controlling interest |
$ |
42,517 |
$ |
— |
||
|
Issuance of common stock for Series C Preferred Stock conversion |
$ |
15,508 |
$ |
— |
||
SOURCE
| Wordcount: | 3364 |


Advisor News
- Succession planning: Building the future of your practice
- From loss to security: Supporting widowed clients with life insurance
- Plan now for lower Social Security benefits later
- The conversation almost no advisor is having yet
- Why advisors should offer retirement-longevity planning
More Advisor NewsAnnuity News
- Empower Annuity Insurance Company of America Trademark Application for “EMPOWER WHAT’S NEXT” Filed: Empower Annuity Insurance Company of America
- Industry pushes back on linking ‘financial strength’ to annuity illustrations
- Sammons Enterprises & Sammons Financial Group Respond to Reports
- The Manhattan Life Insurance Company Acquires Union Security Life Insurance Company of New York
- Cayman Islands premier to meet with U.S. reinsurance regulators
More Annuity NewsHealth/Employee Benefits News
Life Insurance News
- An Application for the Trademark “LIVE TODAY, SECURE TOMORROW.” Has Been Filed by Security Mutual Life Insurance Company of New York: Security Mutual Life Insurance Company of New York
- Modern Woodmen board selects Shea Doyle as next president and CEO
- New Influenza Study Results from University of Auckland Described (Risk Management In Deadly Times: the Us Life Insurance Industry In the 1918-9 Influenza Pandemic): Influenza
- AM Best Assigns Credit Ratings to InEvo Re Ltd.
- Life Insurance Awareness Month: Time to Reassess Your Coverage
More Life Insurance News